Photrexa cross-linking kit 6ML
Ended Awarded Last action
- Contract number
- SPE2DR26FSQS1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,067
Award facts
- Contract value 100% obligated
- $3,067.45 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $3,067.45 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Photrexa Cross-Linking Kit 6ml. The delivery order, issued on January 13, 2026, with an ultimate completion date of February 4, 2026, carries no set-aside designation, indicating the award was made through unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (SPE2DR) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that was awarded on November 13, 2025, with a $499,999,999 ceiling value and completion date of December 31, 2036.
DMS Pharmaceutical Group serves as a critical pharmaceutical supplier within the Defense Logistics Agency's Medical Supply Chain division, authorized to provide branded and generic prescription drugs, biologics, over-the-counter medications, and specialized medical consumables to support Department of Defense healthcare operations worldwide. The company's established performance record across numerous delivery orders, which have ranged from under $100 to over $115,000, demonstrates its capability to fulfill the diverse pharmaceutical requirements of military healthcare facilities. The PPV-G GEN V contract structure includes a 30-month base period with three 30-month option periods and positions DMS Pharmaceutical Group as one of multiple regional prime vendor contractors supporting recurring medical supply needs across the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FSQS1?
SPE2DR26FSQS1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 13, 2026.
How much is contract SPE2DR26FSQS1 worth?
The government has obligated $3,067 on SPE2DR26FSQS1.
Is contract SPE2DR26FSQS1 an order under another contract?
Yes. SPE2DR26FSQS1 is a delivery order under SPE2DR25D9348, an indefinite delivery contract.
Was contract SPE2DR26FSQS1 competed?
The extent of competition for SPE2DR26FSQS1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award